Tempus AI Inc. (NASDAQ:TEM) shares are trading higher on Friday as traders continue to digest the latest follow-through from this week’s Merck–Moderna clinical-trial headline.
Tempus AI stock is gaining positive traction. What’s pushing TEM stock higher?
What Sparked Tempus AI’s Recent Price Action?
The recent spark for TEM was Phase 3 INTerpath-001 results from Merck & Co. and Moderna Inc., where intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda improved recurrence-free survival in resected melanoma, described as the first successful Phase 3 readout for a custom mRNA-based cancer treatment.
The personalized vaccine relies on Personalis Inc.’s genomic tumor-profiling technology, which Moderna uses to analyze patient tissue and identify specific neoantigens for custom doses.
